
PDS Biotechnology Corporation (NASDAQ:PDSB – Free Report) – Equities researchers at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of PDS Biotechnology in a report released on Friday, November 13th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.44) per share for the year, up from their prior estimate of ($0.49). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for PDS Biotechnology’s Q4 2026 earnings at ($0.07) EPS, FY2027 earnings at ($0.18) EPS and FY2028 earnings at ($0.14) EPS.
Other analysts have also issued reports about the company. B. Riley Financial restated a “buy” rating and issued a $4.00 price target (up from $3.00) on shares of PDS Biotechnology in a report on Thursday, October 29th. Wall Street Zen raised PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Monday, October 5th. Finally, Weiss Ratings upgraded PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 28th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, PDS Biotechnology presently has an average rating of “Hold” and a consensus target price of $9.50.
PDS Biotechnology Trading Up 3.0%
PDSB stock opened at $0.81 on Wednesday. The stock has a 50-day moving average price of $1.03 and a two-hundred day moving average price of $0.84. PDS Biotechnology has a 1 year low of $0.20 and a 1 year high of $1.79.
PDS Biotechnology (NASDAQ:PDSB – Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02).
Institutional Investors Weigh In On PDS Biotechnology
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Militia Capital Management LLC raised its stake in PDS Biotechnology by 400.5% in the third quarter. Militia Capital Management LLC now owns 1,660,578 shares of the company’s stock valued at $1,247,000 after buying an additional 1,328,778 shares during the period. BlackRock Inc. bought a new position in shares of PDS Biotechnology during the 2nd quarter worth approximately $535,000. Virtu Financial LLC bought a new position in shares of PDS Biotechnology during the 3rd quarter worth approximately $210,000. Tocqueville Asset Management L.P. acquired a new position in shares of PDS Biotechnology during the 3rd quarter worth approximately $130,000. Finally, Provenance Wealth Advisors LLC acquired a new position in shares of PDS Biotechnology during the 3rd quarter worth approximately $59,000. Institutional investors own 26.84% of the company’s stock.
About PDS Biotechnology
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company developing immunotherapies designed to stimulate the immune system to fight cancer. The company’s research focuses on treatments for HPV-associated cancers and other solid tumors. Its pipeline includes PDS0101, an investigational immunotherapy targeting cancers associated with human papillomavirus 16 (HPV16). The candidate uses the company’s Versamune platform and is being studied in clinical trials, including in combination with other cancer treatments.
Recommended Stories
- Five stocks we like better than PDS Biotechnology
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
